Years earlier, well before clear abnormalities appear on brain scans
In the long human struggle against the slow erasure of memory, Boston researchers have found a new way to listen earlier. Scientists at Mass General Brigham have identified that a protein fragment in the blood — phosphorylated tau 217 — can signal the biological beginnings of Alzheimer's disease years before brain scans reveal any trace of it, offering the possibility that prevention might one day begin long before harm is done. The discovery, drawn from eight years of following hundreds of cognitively healthy adults, suggests that the earliest chapter of this disease can now be read in a simple blood draw — and that for some, the story might yet be changed.
- A blood test for pTau217 can detect Alzheimer's warning signs years before PET brain scans show any abnormality, upending what scientists thought was the earliest possible detection window.
- Among 317 cognitively healthy adults tracked for eight years, those with elevated pTau217 levels accumulated Alzheimer's pathology faster — even when their initial brain scans looked completely normal.
- Crucially, participants with low pTau217 levels were very unlikely to develop significant amyloid buildup over the study period, giving the test predictive power in both directions.
- Researchers see the test as a scalable, affordable gateway to prevention trials — a way to identify at-risk individuals far earlier and far more cheaply than lumbar punctures or brain imaging allow.
- The field is moving quickly: the FDA approved the first Alzheimer's blood test last year, and scientists believe routine pTau217 screening in clinical practice may not be far behind.
A simple blood test may be able to catch Alzheimer's disease a decade or more before a person notices anything wrong. Researchers at Mass General Brigham have found that measuring a protein fragment called phosphorylated tau 217 can reveal the earliest biological signs of the disease in people who are still thinking and remembering perfectly well.
For years, PET brain scans were considered the earliest reliable window into Alzheimer's — capable of spotting amyloid buildup ten to twenty years before symptoms appeared. The new research suggests that window opens even earlier. The pTau217 blood test appears to detect changes before those scans show any abnormalities at all. "We used to think PET scan detection was the earliest sign," said lead author Hyun-Sik Yang. "But now we are seeing that pTau217 can be detected years earlier."
The study followed 317 cognitively healthy adults between ages fifty and ninety for an average of eight years through the Harvard Aging Brain Study. People with higher pTau217 levels showed faster accumulation of Alzheimer's pathology even when their initial brain scans looked normal — and those with low levels were very unlikely to develop significant amyloid buildup over the follow-up period.
Researchers are careful not to overreach. Universal screening isn't yet recommended. But they see a clear path: the blood test could first serve as a recruitment tool for prevention trials, identifying high-risk individuals earlier and more affordably than existing methods. Over time, it might become part of routine checkups. "By anticipating who's going to turn amyloid-positive in the future, we are trying to push back the clock," said co-senior author Jasmeer Chhatwal. The FDA approved the first Alzheimer's blood test last year, and the distance between laboratory discovery and clinical practice is shrinking.
A simple blood test might catch Alzheimer's disease a decade or more before a person notices anything wrong. Researchers at Mass General Brigham have found that measuring a protein fragment called phosphorylated tau 217 in the bloodstream can reveal the earliest biological signs of the disease in people who still think and remember perfectly well.
For years, doctors believed that PET brain scans showed the first real evidence of Alzheimer's—they could spot the accumulation of amyloid protein in the brain ten to twenty years before symptoms arrived. But the new work suggests that's not quite right. The blood test for pTau217 appears to catch the disease even earlier, years before those brain scans light up with abnormalities. "We used to think PET scan detection was the earliest sign," said Hyun-Sik Yang, a neurologist at Mass General Brigham and lead author of the study. "But now we are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans."
The discovery matters because it opens a door to prevention. Last year the FDA approved the first blood test for Alzheimer's, clearing the way for something far cheaper and less invasive than the lumbar punctures and brain imaging that doctors have relied on. The new research from Boston adds weight to the idea that these blood tests could actually work—that they could identify people at risk long before damage becomes visible.
The study followed 317 cognitively healthy adults, ranging from age fifty to ninety, for an average of eight years as part of the Harvard Aging Brain Study. Researchers measured pTau217 levels in their blood, tracked changes on repeated PET scans, and tested their thinking and memory over time. What they found was striking: people with higher pTau217 levels showed faster buildup of Alzheimer's pathology—the accumulation of amyloid and tau proteins in the brain—even when their initial scans looked completely normal. The increases in pTau217 often happened before the amyloid scans turned positive, suggesting the blood test was catching something real and important.
Equally important was what didn't happen. People who started the study with low pTau217 levels were very unlikely to accumulate significant amyloid on their brain scans over the years of follow-up. "What stood out in our study is that even when amyloid scans appear normal in the clinic, the pTau217 biomarker can identify individuals who later become amyloid-positive," Yang said. "It also shows that those with low pTau217 levels are likely to stay amyloid-negative for several years."
The researchers are careful not to oversell what they've found. It's too early to start testing every older adult for pTau217. But they see a clear path forward. The blood test could become a screening tool for clinical trials testing whether drugs can prevent Alzheimer's in people at high risk—a way to find the right people to study. Eventually, it might become part of routine health checkups, offering a much cheaper alternative to PET scans. "By anticipating who's going to turn amyloid-positive in the future, we are trying to push back the clock to enable earlier Alzheimer's disease prediction," said Jasmeer Chhatwal, a co-senior author. The field is moving fast, and what starts in the lab often reaches patients sooner than anyone expects.
Notable Quotes
We used to think PET scan detection was the earliest sign of Alzheimer's disease progression. But now we are seeing that pTau217 can be detected years earlier.— Hyun-Sik Yang, neurologist, Mass General Brigham
By anticipating who's going to turn amyloid-positive in the future, we are trying to push back the clock to enable earlier Alzheimer's disease prediction.— Jasmeer Chhatwal, neurologist, Mass General Brigham
The Hearth Conversation Another angle on the story
Why does it matter that we can detect this protein years before symptoms show up? If someone feels fine, does knowing they're at risk actually help them?
That's the crucial question. Right now, we don't have proven ways to stop Alzheimer's once it starts. But we're getting closer to drugs that might slow it down—and those drugs probably work better the earlier you catch the disease. If you can identify someone ten years before they'd notice memory problems, you have a window to try prevention.
So this blood test is really a recruitment tool for drug trials, not a diagnostic tool yet.
Exactly. That's the honest version. It's a way to find people who are biologically on the path to Alzheimer's so researchers can test whether interventions actually work. The hope is that if prevention drugs prove effective, then yes, the test becomes something doctors use routinely.
How reliable is it? Can you trust a blood test more than a brain scan?
The study shows it's picking up real biology—the people with high pTau217 levels did go on to show brain changes. But it's not perfect. It's a biomarker, a signal. It doesn't mean someone will definitely get Alzheimer's, just that they're at higher risk. The brain scans are still the gold standard for seeing actual damage.
What about the people with low levels? Can they relax?
The study suggests they can, at least for several years. People who started with low pTau217 rarely accumulated amyloid on their scans over the eight-year follow-up. But this is still a snapshot. Biology changes. You'd probably need periodic testing to stay confident.
Is this test available now?
The FDA cleared a blood test for Alzheimer's last year, so yes, it exists. But it's not standard care yet. Most people aren't getting tested. That will probably change as more evidence accumulates and as prevention strategies become available.